MAPT and tauopathy: Thus, we have shown here that targeting ac-tauK174 in a model of tauopathy improves cognitive function and mitigates tau pathology, consistent with our previous reports using small molecule inhibitors of the tau acetyltransferase p300/CBP [13, 37].